{"name": "Seattle Genetics",
 "permalink": "seattle-genetics",
 "crunchbase_url": "http://www.crunchbase.com/company/seattle-genetics",
 "homepage_url": "http://www.seagen.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "contact@seagen.com",
 "phone_number": "(425) 527-4000",
 "description": "",
 "created_at": "Wed Jan 19 02:23:47 UTC 2011",
 "updated_at": "Sat Jan 26 00:52:48 UTC 2013",
 "overview": "\u003Cp\u003ESeattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company\u00e2\u20ac\u2122s other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       38],
      "assets/images/resized/0011/7993/117993v1-max-150x150.jpg"],
     [[250,
       64],
      "assets/images/resized/0011/7993/117993v1-max-250x250.jpg"],
     [[331,
       85],
      "assets/images/resized/0011/7993/117993v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and CEO",
    "person":
     {"first_name": "Clay",
      "last_name": "B. Siegall",
      "permalink": "clay-b-siegall",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Todd",
      "last_name": "E. Simpson",
      "permalink": "todd-e-simpson",
      "image": null}},
   {"is_past": false,
    "title": "VP, Medical Affairs",
    "person":
     {"first_name": "James",
      "last_name": "Kyle Bryan",
      "permalink": "james-kyle-bryan",
      "image": null}},
   {"is_past": true,
    "title": "Chairman of the Board",
    "person":
     {"first_name": "Perry",
      "last_name": "Fell",
      "permalink": "perry-fell",
      "image": null}},
   {"is_past": true,
    "title": "VP, Preclinical Therapeutics",
    "person":
     {"first_name": "Iqbal",
      "last_name": "Grewal",
      "permalink": "iqbal-grewal",
      "image":
       {"available_sizes":
         [[[104,
            104],
           "assets/images/resized/0027/1954/271954v1-max-150x150.jpg"],
          [[104,
            104],
           "assets/images/resized/0027/1954/271954v1-max-250x250.jpg"],
          [[104,
            104],
           "assets/images/resized/0027/1954/271954v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Sr.Director, Analytical Biochemistry \u0026 Formulations",
    "person":
     {"first_name": "Claudia",
      "last_name": "Jochheim",
      "permalink": "claudia-jochheim",
      "image":
       {"available_sizes":
         [[[150,
            140],
           "assets/images/resized/0025/2287/252287v1-max-150x150.jpg"],
          [[200,
            187],
           "assets/images/resized/0025/2287/252287v1-max-250x250.jpg"],
          [[200,
            187],
           "assets/images/resized/0025/2287/252287v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Executive Vice President, Commercial",
    "person":
     {"first_name": "Bruce",
      "last_name": "J. Seeley",
      "permalink": "bruce-j-seeley",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0027/2654/272654v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0027/2654/272654v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0027/2654/272654v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Director",
    "person":
     {"first_name": "Daniel",
      "last_name": "F. Hoth",
      "permalink": "daniel-f-hoth",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$155M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.fiercebiotech.com/story/seattle-genetics-raises-155m-chelsea-splits-trial-northera/2011-02-02?utm_medium=rss\u0026utm_source=rss",
    "source_description": "Seattle Genetics raises $155M; Chelsea splits trial for Northera",
    "raised_amount": 155000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 2,
    "funded_day": 2,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "21823 - 30th Drive S.E.",
    "address2": "",
    "zip_code": "98021",
    "city": "Bothell",
    "state_code": "WA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Seattle Genetics scores $208M Pfizer pact for ADC tech",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 6,
    "source_url": "http://www.fiercebiotech.com/story/seattle-genetics-scores-208m-pfizer-pact-adc-tech/2011-01-06?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Seattle Genetics scores $208M Pfizer pact for ADC tech",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Seattle Genetics",
      "permalink": "seattle-genetics"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:SGEN"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}